Akebia Therapeutics, Inc. (NASDAQ: AKBA) today announced full enrollment of its global Phase 3 INNO2VATE studies for vadadustat, that it ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Management Changes Management Comments

Akebia Therapeutics (AKBA) Misses Q1 EPS by 22c, Revenues MissMay 9, 2019 8:10 AM Akebia Therapeutics Reports First Quarter 2019 Financial Results; Announces Full Enrollment of Phase 3 INNO2VATE Studies and Announces Key Executive AppointmentsMay 9, 2019 8:00 AM